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INTRODUCTION
Preamble
The prevalence of nonalcoholic fatty liver disease (NAFLD) is in-
creasing rapidly worldwide as the obese and diabetic populations 
increase, and it has been estimated to be 20–30% in Korea. Con-
sidering the increased popularity of a westernized diet and life-
style, lack of exercise, and the resulting increase in obesity and di-
abetes, NAFLD is predicted to become more prevalent in the 
future and to become a major cause of chronic liver disease. In 
some patients, NAFLD progresses to end-stage liver diseases such 
as cirrhosis and hepatocellular carcinoma (HCC), and it is an inde-
pendent cardiovascular risk factor.
In 2013, the Korean Association for the Study of the Liver 
(KASL) enacted a clinical practice guideline for the diagnosis and 
treatment of NAFLD to improve understanding of the disease and 
provide useful clinical information and direction for healthcare 
providers. The research results that have accumulated since then 
necessitate a revision. Accordingly, the clinical practice guidelines 
committee began revising the guidelines to reflect the results of 
Korean and international research and develop new recommenda-
tions based on a systematic approach that reflects evidence-
based medicine and expert opinions. However, evidence remains 
insufficient, and many studies are currently being conducted. As 
medical evidence and new findings accumulate in the future, 
these guidelines will require ongoing supplementation and revision.
Target population
Patients diagnosed with NAFLD based on clinical, biochemical, 
radiological, or pathological findings in the absence of significant 
alcohol consumption and liver diseases such as viral hepatitis 
were the primary research population involved in the development 
of these guidelines. These guidelines are also based on data from 
pediatric and adolescent NAFLD patients, whose unique findings 
distinguish them from adult NAFLD patients.
Intended users
The aim of these guidelines is to provide useful clinical informa-
tion and direction to healthcare providers involved in the diagno-
sis and treatment of NAFLD patients. Moreover, these guidelines 
are intended to provide definite and practical information to resi-
dent physicians, practitioners, and trainers.
Developer and funding information
The Clinical Practice Guideline Committee for the Management 
of NAFLD (Committee) was organized in accordance with propos-
als by the approval of the KASL Board of Executives and consists 
of 16 gastroenterologists, one pathologist, one radiologist, and 
two pediatricians specializing in hepatology. All expenses were 
paid by KASL. Each committee member collected and analyzed 
the source data in his or her own field, and the members then 
wrote the manuscript together.
Evidence collection
The committee systematically collected and reviewed the inter-
national and domestic literature published in PubMed, MEDLINE, 
KoreaMed, and other databases. The literature was limited to re-
search papers published in the English and Korean languages. The 
keywords used were ‘nonalcoholic fatty liver disease,’ ‘nonalco-
holic fatty liver,’ ‘nonalcoholic steatohepatitis,’ ‘fatty liver,’ ‘hepat-
ic steatosis,’ and ‘steatohepatitis.’ In addition, keywords related to 
specific clinical questions were included.
Levels of evidence and grades of recommendations
The literature gathered for data collection was analyzed in a 
systematic review, and the quality of evidence was classified 
based on the modified Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) system (Table 1). Ac-
cording to the types of studies, randomized, controlled studies 
were approached from a high level of evidence, while observa-
tional studies were approached from a low level of evidence. Sub-
sequently, the level of evidence basis sets in corresponding stud-
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ies was elevated or lowered by accounting for the factors 
influencing the quality of the studies. Through follow-up studies, 
the level of evidence was defined as follows: A, indicating the 
highest level of evidence with the smallest possibility of any 
changes in the conclusion; B, indicating a moderate level of po-
tential changes; and C, indicating the lowest level of evidence 
with the greatest possibility of any changes.
The strength of each recommendation was suggested according 
to the GRADE system. In addition to the level of evidence, the re-
sults of studies were considered based on aspects of clinical mul-
tipliers and socio-economic factors, such as cost. Grading of the 
recommendations was performed as follows: 1, strong recom-
mendation or 2, weak recommendation. A strong recommenda-
tion indicated, for example, that the interventions could be ap-
plied in most patients with strong certainty, there was a greater 
possibility of desirable effects, and there was high-quality evi-
dence, as well as presumed patient-important outcomes, cost-ef-
fectiveness, preference, and compliance. A weak recommendation 
indicated a suggestion made with less certainty but that could be 
considered favorable for many patients. Alternative interventions 
could be chosen for “weak recommendations”, according to cost 
and the preferences of the patients or medical practitioners.
These Clinical Practice Guidelines for the Management of 
NAFLD have been developed through the reviews of medical ex-
perts to be used practically for treatment, research, and educa-
tion. These recommendations are not absolute standards for 
treatment, and adoption of these guidelines in clinical practice 
can differ for individual patients.
List of key questions
The committee considered the following clinical questions as 
key components to be covered in the guidelines.
1. What are the definition and categories?
2. What are the incidence rate and prevalence rate?
3. How does NAFLD progress?
4. What causes NAFLD-related deaths?
5. What are the risk factors of NAFLD?
6. What are NAFLD’s comorbidities?
7.  Who should be targeted for NAFLD screening, and how is 
screening conducted?
8.  Which non-invasive surrogates are available to diagnose he-
patic steatosis?
9.  Which non-invasive surrogates are available to diagnose 
NASH?
10.  Which non-invasive surrogates are available to assess liver 
fibrosis?
11. Which differential tests are available for advanced fibrosis?
12. What are the indications for liver biopsy?
13. What are the histopathological features of NAFLD?
14. Is surveillance for HCC necessary?
15. How can HCC be prevented?
16.  Who should be treated, and what is the aim of the treat-
ment?
17. What do lifestyle modifications include?
18. What is the effect of moderate or less alcohol consumption?
19.  What are the types, indications, effects, and side effects of 
medications for NAFLD?
20.  What are the indications for and post-operative manage-
Table 1. The grading of recommendations, assessment, development, and evaluation (GRADE) system
Criteria
Quality of evidence
High quality Further research is very unlikely to change our confidence in the estimate of the effect. A
Moderate quality Further research is likely to have an important impact on our confidence in the estimate of the effect 
and may change the estimate.
B
Low quality Further research is very likely to have an important impact on our confidence in the estimate of the 




Strong Factors influencing the strength of the recommendation include the quality of the evidence, presumed 
patient-important outcomes, and cost.
1
Weak Variability in preference and values or greater uncertainty. The recommendation is made with less 
certainty, higher cost or resource consumption.
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ment of bariatric surgery?
21.  What are the indications for liver transplantation (LT) and 
post-LT management?
Regarding NAFLD in children and adolescents:
1. What is the prevalence rate? 
2. How does NAFLD progress? 
3. What genetic diseases are associated with risk factors? 
4.  Is related NAFLD related to family history and genetic predis-
position? 
5.  Who should be targeted for NAFLD screening, and how is 
screening conducted? 
6. What are the diagnostic methods? 
7. Who should be treated, and how?
Review of the manuscript and approval process
The manuscripts written by the committee members were re-
viewed and approved through meetings of the committee. The 
quality of the manuscripts was evaluated based on the integrity of 
the contents and the standards of Appraisal of Guidelines for Re-
search and Evaluation II (AGREE II). The guidelines were also re-
viewed at a meeting of an external review board consisting of 11 
specialists in the field of hepatology and at a symposium open to 
all KASL members, and they were then further modified prior to 
publication. The final manuscript was endorsed by the Board of 
Executives of KASL.
Release of the guidelines and plan for updates
The Korean version of the KASL Clinical Practice Guideline for 
the Management of NAFLD was released at Liver Week 2021 (May 
15, 2021), and published in the Clinical and Molecular Hepatology 
(July 2021). This guideline in Korean is available on the KASL 
website (http://www.kasl.org). Updates are planned when new 
reliable evidence has accumulated. Detailed plans for updates will 
be posted on the KASL website.
DEFINITION
What are the definition and categories?
NAFLD is a condition characterized by finding fat infiltration of 
the liver on radiological exams or biopsy without significant alco-
hol intake, viral hepatitis, medication intake that would cause a 
fatty liver, or other obvious cause. NAFLD is defined as a disease 
with findings suitable for clinical, biochemical, imaging, and path-
ological examinations. NAFLD is a generic term that encompasses 
the spectrum of nonalcoholic fatty liver (NAFL), nonalcoholic ste-
atohepatitis (NASH), and NASH cirrhosis (Table 2). The significant 
safe limits of daily alcohol intake that distinguish NAFLD from al-
coholic fatty liver disease range from 10–40 g (pure alcohol), 
though that range varies between studies. Therefore, definite cri-
teria are difficult to recommend. The Clinical Practice Guideline of 
the European Association for the Study of the Liver agreed to de-
fine the amount of significant alcohol consumption as weekly al-
cohol consumption ≥210 g in men and ≥140 g in women.1 No 
ethnic differences have been reported regarding safe alcohol lim-
its that do not produce liver damage. The KASL Clinical Practice 
Guideline for NAFLD uses the amount of significant alcohol con-
sumption stated above in clinical treatment and in studies for in-
ternational comparison with the results of future studies.
The term NAFLD was introduced by Schaffner in 1986.2 Howev-
er, as information about the causes and mechanisms of the dis-
ease accumulated, an opinion emerged that the term NAFLD does 
not reflect the condition’s heterogeneous pathogenesis and vari-
ous courses. Furthermore, the overestimation of the exclusion of 
alcohol has sparked heated debate about the threshold of “signif-
Table 2. Definition of nonalcoholic fatty liver disease-related terms
Term Definition
NAFLD NAFLD is a generic term encompassing a spectrum of liver disorders, including nonalcoholic fatty liver, NASH, and 
NASH cirrhosis. Fat accumulation of more than 5% of the liver’s weight in a biopsy is defined as fat infiltration.
NAFL (simple steatosis) This condition is characterized by fat infiltration of the liver without findings of ballooning degeneration or fibrosis.
NASH This condition is characterized by fat infiltration of the liver along with findings of inflammation associated with 
ballooning degeneration. It is occasionally associated with fibrosis.
NASH cirrhosis This condition is characterized by cirrhosis associated with NAFL or NASH, or cirrhosis occurring in patients with NAFL 
or NASH as proven by past histology.
NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NAFL, nonalcoholic fatty liver.
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icant” alcohol consumption required for the diagnosis of NAFLD, 
and the potential (contradictory) role of alcohol consumption in 
these “non-alcohol” diseases has been repeatedly raised. In 2019, 
a consensus by 32 experts suggested alternative terminology, 
metabolic (dysfunction)-associated fatty liver disease (MAFLD), to 
more accurately reflect the pathogenesis of this disease.3 The di-
agnosis of MAFLD is based on evidence of fat accumulation in the 
liver in the presence of one of the following three criteria: over-
weight/obesity, type 2 diabetes mellitus (T2DM), and evidence of 
metabolic dysregulation. Further research results are needed to 
verify the validity of this term.
EPIDEMIOLOGY
What are the incidence rate and prevalence rate?
Incidence
In 2007, researchers published results from tracking 5,237 men 
for more than 4 years and reported for the first time that the an-
nual incidence of NAFLD was 74.1 cases per 1,000 persons.4 The 
annual incidence rate of NAFLD diagnosed by abdominal ultraso-
nography in health screening examinees was about 48.2 cases 
per 1,000 persons (range, 13.4–77.7).5-11 As diagnosed by the he-
patic steatosis index (HSI), the annual incidence rate was 21.1 
cases per 1,000 persons.12 According to a meta-analysis in Asia, 
the annual incidence rate in Korea was 45.1 cases per 1,000 per-
sons.13,14
Prevalence
The prevalence of NAFLD varies depending on the study popu-
lation, definition of NAFLD, and diagnostic modality. In 2002, the 
prevalence among 1,074 people receiving health checkups and di-
agnosed by abdominal ultrasound was 48.6%.15 The prevalence 
among 141,610 people receiving health checkups in the Seoul 
and Gyeonggi area and diagnosed by abdominal ultrasound was 
25.2% (male, 34.4%; female, 12.2%),16 and the prevalence in 
other studies varied from 21% to 44%.17-23 In a meta-analysis, the 
prevalence in Korea, as diagnosed by ultrasonography, was 
32.9%.13
The prevalence diagnosed using the fatty liver index (FLI) was 
12.6–16.1%,22,24 and the prevalence diagnosed with transient 
elastography was 42.9%.25 The prevalence diagnosed by liver bi-
opsy among 589 living liver donors in Korea was 51%.26
Lean/non-obese NAFLD
People with normal body weight (body mass index [BMI; kg/m2] 
of less than 23 kg/m2 for Asians, less than 25 kg/m2 for Western-
ers) or non-obese weight (BMI of less than 25 kg/m2 for Asians, 
less than 30 kg/m2 for Westerners) can also be diagnosed with 
NAFLD, but data on the incidence rate among those people in Ko-
rea are limited. In 2004, the prevalence of NAFLD was 16.1% 
among 460 people with a BMI between 18.5 kg/m2 and 25 kg/m2 
who received domestic health checkups.27 In several domestic 
studies, the average prevalence of non-obese NAFLD was 18.8% 
(12.4–27.1%).28-34
Summary
1.  The annual incidence of NAFLD in Korea is about 45 cases per 
1,000 persons.
2.  The prevalence of NAFLD in Korea is approximately 30%.
3.  The prevalence of nonalcoholic fatty liver disease in the 
domestic non-obese population is about 19%.
Natural course and cause of death
How does NAFLD progress?
Because the natural course of NAFLD can only be confirmed 
through repeated liver biopsy, it has been reported only in small 
studies. The incidence of NASH was reported to vary from 8.5% 
to 64.0% over a 3.0–6.6 years follow-up period, a large variation 
that appears to result from differences in the number of patients, 
various follow-up periods, and diagnostic criteria.35-37
In a meta-analysis comparing NAFL and NASH, the percentage 
of patients who progressed to more than one stage of liver fibro-
sis were similar at 39.1% and 34.5%, respectively, but the time it 
took those patients to progress more than one stage was 14.3 
years and 7.1 years, respectively. NASH thus showed faster pro-
gression.38
In a cohort study of NASH patients, the incidence of cirrhosis 
varied by race and region, with an average of 21–26% of patients 
progressing to cirrhosis in eight years.39,40 According to a study of 
an LT waitlist, the number of patients with end-stage liver disease 
because of NAFLD had tripled from 10 years previously, making 
NAFLD the second most common reason for needing LT.41 
Recently, HCC caused by NAFLD has rapidly increased, becom-
ing the third most common cause of HCC development in United 
States, and that number is expected to increase by 9% per 
year.42,43 This trend is believed to be due to the rapid increase in 
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the prevalence of obesity, which is a risk factor for NAFLD. NAFLD 
is associated with a higher incidence of HCC than other etiologies 
of liver disease in the absence of advanced fibrosis or cirrhosis.44-46
What causes NAFLD-related deaths?
According to data from the U.S. National Vital Statistics System, 
the mortality rate of NAFLD has increased in the past decade.47 In 
a meta-analysis, patients with NAFLD had a 1.6 times higher mor-
tality rate than the general population. The major causes of death 
were cardiovascular disease (CVD), malignancy, and liver disease, 
and in the presence of steatohepatitis, liver disease-related deaths 
increased.48-50 In several cohort studies, the prognosis of patients 
with NAFLD was most closely related to the degree of liver fibro-
sis.51,52 In a large-scale cohort study based on liver biopsy, the 
mortality rate of NAFL patients was 1.7 times that of the normal 
control group; the mortality rate of patients who had steatohepa-
titis without hepatic fibrosis was 2.1 times that of the normal con-
trol group; patients with liver fibrosis had a mortality rate 2.4 
times that of the normal control group; patients with cirrhosis had 
a mortality rate that was 3.8 times that of the normal control 
group. Thus, the mortality rate increased with the degree of liver 
fibrosis.53
Summary
1. Liver fibrosis can progress faster in NASH than in NAFL.
2.  The incidence of liver cirrhosis and HCC associated with 
NAFLD is increasing, and HCC can develop even in the 
absence of liver cirrhosis.
3.  The main causes of death among patients with NAFLD are 
CVD, malignant tumors, and liver diseases, and liver disease-
related mortality increases when steatohepatitis and liver 
fibrosis are present.
What are the risk factors of NAFLD?
NAFLD is closely related to obesity, diabetes, dyslipidemia, and 
metabolic syndrome (Fig. 1). Obesity is a well-known risk factor 
for NAFLD, and the prevalence of NAFLD increases as BMI in-
creases.54 Among obese patients who underwent bariatric sur-
gery, the prevalence of NAFL, NASH, and significant liver fibrosis 
were 61–91%, 30–37%, and 29.3%, respectively.55,56 Metabolic 
syndrome, which consists of abdominal obesity, impaired fasting 
blood sugar, hypertriglyceridemia, low high-density cholesterol-
emia, and hypertension, is a major risk factor for NAFLD, just like 
obesity. In the presence of metabolic syndrome, the prevalence of 
NAFLD was 50%.57,58 The prevalence of NAFLD was also high in 
diabetic patients, 60–75%.14 In patients with dyslipidemia, anoth-
er risk factor, the prevalence of NAFLD was 50%.59,60
In the presence of hypothyroidism, the prevalence of NAFLD in-
creases by 1.6 times,61 and in the presence of polycystic ovary 
syndrome, the incidence increases by about 2.2 times.62 In addi-
tion, obstructive sleep apnea,63 hypopituitarism,64 hypogonad-
ism,65 pancreatoduodenal resection,66 and psoriasis67 increase the 
prevalence of NAFLD.
Decreased physical activity and sarcopenia increase the risk of 
NAFLD.68,69 The prevalence and incidence of NAFL increased in 
the group with reduced physical activity.70-72 In the presence of 
sarcopenia, the risk of NAFLD increased by about four times re-
gardless of obesity or metabolic syndrome.68,69 When sarcopenia 
was accompanied by NAFLD, the risk of advanced liver fibrosis in-
creased by 1.8 times.69 
Genetic factors play a major role in the occurrence of NAFLD. 
Typically, the patatin-like phospholipase domain-containing 3 
(PNPLA3) and transmembrane 6 superfamily, member 2 (TM6SF2) 
single nucleotide polymorphisms affect the development and pro-
gression of the disease. In Korea, PNPLA3 and sorting and assem-
bly machinery component 50 (SAMM50) were associated with the 
prevalence and severity of NAFLD.73
Summary 
1.  Major risk factors for NAFLD include obesity, diabetes, 
dyslipidemia, and metabolic syndrome.
What are NAFLD’s comorbidities?
NAFLD is closely related to systemic metabolic diseases,74 and it 
is an independent risk factor for the occurrence of various non-
Figure 1. Risk factors for nonalcoholic fatty liver disease.
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hepatic diseases, including CVD, T2DM, metabolic syndrome, 
chronic kidney disease (CKD), and malignant tumors.75-77
CVD
In a retrospective cohort study of 1,804 patients with NAFLD in 
Denmark in the 2000s, the mortality rate from CVD was higher 
than that in the normal control group.50 Several cohort studies 
that followed also found NAFLD to be an independent risk factor 
for CVD.78,79 In a study that followed patients with histologically 
diagnosed NAFLD for an average of 26.4 years, the mortality rate 
increased by 1.3 times, and the risk of CVD increased by 1.6 times 
compared with the normal control group, with both increases as-
sociated with the degree of liver fibrosis.78 A meta-analysis of pa-
tients with NAFLD diagnosed histologically or radiologically con-
cluded that the risk of CVD was increased by about 1.6 times 
compared with the normal control group. The risk of CVD also in-
creased when liver fibrosis was assessed using the NAFLD fibrosis 
score (NFS) or liver biopsy.80 According to two Korean cohort 
studies, NAFLD was independently associated with the incidence 
of coronary artery calcification and atherosclerosis, which are di-
rect causes of CVD.18,81
T2DM
T2DM and NAFLD influence each other.82 In a large-scale cohort 
study of healthy Koreans, the prevalence and incidence of T2DM 
in patients with NAFLD (assessed using the NFS) increased with 
the degree of hepatic fibrosis.17 In a meta-analysis of Korean stud-
ies, the prevalence of diabetes in patients with NAFLD was 
14.2%, higher than the 5.2% of the control group.83 The results 
of a meta-analysis of other studies also showed an increase of 
about 2.2 times in the incidence of T2DM.84
Metabolic syndrome
Metabolic syndrome is a major risk factor for the occurrence of 
NAFLD and is a common comorbid disease. A prospective Korean 
cohort study of 46,874 men reported that patients with mild and 
moderate NAFLD (diagnosed by abdominal ultrasound) had a risk 
of metabolic syndrome 1.5 and 2 times higher, respectively, than 
the control group.85 In a meta-analysis of Korean studies, the inci-
dence of metabolic syndrome was 40.7% in patients with NAFLD 
and 11.2% in the control group.83
CKD
CKD and NAFLD share risk factors such as T2DM and hyperten-
sion,86 and CKD frequency increases in patients with NAFLD.87-89 
In a meta-analysis of about 63,000 people, the prevalence of CKD 
increased by 2.1 times, and the incidence rate increased by 1.7 
times compared with the control group.90 The prevalence and inci-
dence of CKD were 2.5 times and 2.1 times higher in NASH than 
NAFLD. In a Korean cohort study, patients with NAFLD had a 1.2 
times higher risk of developing CKD than the control group, and 
that risk increased with the stage of liver fibrosis.91
Other diseases
Arrhythmia, osteoporosis, colon adenoma, colon cancer, and 
breast cancer all have increased incidence in patients with 
NAFLD.92-94 However, more follow-up studies are needed to con-
firm clear relationships between NAFLD and those diseases.
Summary
1.  NAFLD is often associated with comorbidities such as 
cardiovascular disease, T2DM, metabolic syndrome, CKD, and 
malignant tumors.
DIAGNOSIS
Who should be targeted for NAFLD screening, and 
how is screening conducted?
Screening for NAFLD should be considered in cases of persistent 
liver enzyme elevation. Because the cost effectiveness of screen-
ing in diabetic patients has been confirmed,95 patients with diabe-
tes should receive screening tests for NAFLD regardless of their 
liver enzyme levels. In addition, subjects with metabolic syndrome 
(which is closely associated with insulin resistance), obesity, and 
other risk factors for NAFLD can be considered for screening 
tests.17,96
The primary screening test for NAFLD is ultrasonography. When 
NAFLD is suspected in the ultrasonography results, other tests 
(computed tomography [CT], magnetic resonance imaging [MRI], 
serologic tests, transient elastography, etc.) can be performed.
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[Recommendations]
1.  Subjects who have persistent liver enzyme elevation or 
diabetes should be screened for NAFLD. (A1)
2.  Subjects with metabolic syndrome (which is closely associated 
with insulin resistance, obesity, and other risk factors for 
NAFLD) can be considered for screening. (B1)
3.  Abdominal ultrasonography is the primary screening modality. 
(B1)
Non-invasive examinations
Because the prognosis of NAFLD differs significantly depending 
on the histological findings, the diagnosis of hepatic steatosis and 
fibrosis and assessment of their severity are clinically crucial. To 
date, liver biopsy is the gold standard in assessing hepatic necro-
inflammation, steatosis, and fibrosis. However, liver biopsy is ex-
pensive, invasive, carries a risk of complications, is subject to in-
tra-/inter-observer interpretational variability, and can suffer from 
sampling errors when an insufficient amount of liver tissue is col-
lected.97,98 Therefore, noninvasive radiological surrogates such as 
ultrasonography and panels of serological tests are widely used.
Which non-invasive surrogates are available to diagnose 
hepatic steatosis?
Radiological surrogates
Abdominal ultrasonography is the first-line imaging modality for 
screening asymptomatic patients with abnormal liver enzyme lev-
els. However, it suffers from subjective interpretation, examina-
tion difficulties in obese patients, and low sensitivity when the 
amount of hepatic steatosis is less than 30%. Moreover, ultraso-
nography cannot distinguish NASH from NAFL.99-101 When hepatic 
steatosis assessed using MR spectroscopy (MRS) was used for ref-
erence, the diagnostic accuracy of ultrasonography was lower 
than that of non-contrast CT and MRI.102 However, ultrasonogra-
phy is appropriate as a screening test, because it offers 1) robust 
diagnostic performance for moderate or severe steatosis, 2) the 
ability to evaluate the entire hepatobiliary system in addition to 
detecting the presence of hepatic steatosis, and 3) wide availability.
Controlled attenuation parameter (CAP) is a feature of transient 
elastography that can quantify the degree of fat deposition in the 
liver parenchyma by measuring ultrasound attenuation.103,104 Ac-
cording to a recent Korean study enrolling people who received 
regular health checkups, the normal CAP range is 156–287 dB/m.105 
The area under the receiver operating characteristic curve (AUC) 
of CAP used to diagnose a moderate to severe degree of steatosis 
was 0.88 (sensitivity, 83.3%; specificity, 81.6%), and the cutoff 
value was 276 dB/m in a Korean study of living LT donors.106 In 
another Korean study, the AUCs of CAP for mild, moderate, and 
severe degrees of steatosis in patients with chronic liver diseases, 
including NAFLD, were 0.885, 0.894, and 0.800, respectively, 
and the cutoff values were 250 dB/m, 299 dB/m, and 327 dB/m, 
respectively.107 In a recent meta-analysis, the AUCs of CAP for 
mild, moderate, and severe degrees of steatosis were 0.96, 0.82, 
and 0.70, respectively.108 CAP can be used as a monitoring tool 
for hepatic steatosis, and it can be examined simultaneously with 
transient elastography.109-111 Other ultrasound-based methods, in-
cluding image-based quantitative analysis of liver parenchymal 
echo texture and measuring the attenuation of ultrasound energy, 
are under investigation.112,113
Hepatic steatosis is associated with low attenuation on CT 
scans, which can be used for the quantitative assessment of he-
patic steatosis. Because the attenuation of enhanced CT is affect-
ed mainly by the amount of blood flow, unenhanced CT is favored 
for the measurement of hepatic steatosis, and the attenuation of 
liver and spleen parenchyma are frequently compared. For moder-
ate to severe steatosis, the specificity of CT was reported to be 
high, but its sensitivity and positive predictive value were low.101,114,115 
Furthermore, its diagnostic performance for mild steatosis was 
suboptimal. The specificity and sensitivity of unenhanced CT for 
diagnosing moderate to severe steatosis were 100% and 53.8%, 
respectively, when CT attenuation of hepatic parenchyma was 
less than 48 HU.115 However, CT raises concerns about radiation 
hazards, and CT evaluations of hepatic steatosis are limited in pa-
tients with infiltrative liver diseases that deposit iron, copper, gly-
cogen or amiodarone in the liver parenchyma because CT attenu-
ation is affected by those materials.116,117 Dual energy CT, which 
adopts two different tube potentials for image acquisition, can 
perform material decomposition and has been used to quantify 
the degree of hepatic steatosis.102
MRI is superior to ultrasonography for measuring a small 
amount of fat in the liver, and it is the most precise imaging tool 
for evaluating NAFLD. Quantitative MRI measurements of hepatic 
fat deposition using the Dixon technique can be classified into 
MRS and MRI proton density fat fraction (MRI-PDFF).118 MRS can 
directly measure the signal from acryl groups of triglycerides, and 
MRS findings correlate closely with histological results and show 
high sensitivity to hepatic steatosis.119,120 MRI-PDFF uses differenc-
es in the precession frequency of water and fat protons and can 
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map the entire liver for the degree of steatosis. Therefore, it can 
measure the degree of fat deposition in any part of the liver pa-
renchyma. MRI-PDFF in different MRI units is in high agreement 
with histological findings, and its diagnostic performance in de-
tecting severe steatosis (≥67%) was high (AUC, 0.95).121,122 In a 
recent meta-analysis, the AUCs for differentiating grade 1–3 ste-
atosis, grade 2–3 steatosis, and grade 3 steatosis were 0.98, 0.91, 
and 0.90, respectively.123 MRI-PDFF showed superior diagnostic 
performance to CAP in assessing hepatic steatosis in a prospec-
tive study.124 MRS and MRI-PDFF can measure the degree of ste-
atosis precisely, irrespective of iron deposition or fibrosis.125 De-
spite the superior diagnostic performance of MRS and MRI-PDFF, 
their limited availability and high cost remain problems.
Panels
In addition to radiological examinations, various panels of sero-
logical tests have been proposed to diagnose hepatic steatosis 
and assess its severity (Table 3). These panels can be calculated 
using clinical information such as age, sex, and the results from 
serological tests. These panels do not directly diagnose hepatic 
steatosis, unlike ultrasonography, but they can help physicians 
who suspect the presence of hepatic steatosis to decide whether 
further assessments are justified. Large-scale studies frequently 
use these noninvasive panels to test for hepatic steatosis instead 
of ultrasonography, which has a high cost.
The FLI was proposed by Bedogni et al.126 in an Italian study 
that examined 216 subjects with liver disease and 280 subjects 
with healthy livers. In that study, 228 patients had ultrasonogra-
phy-defined NAFLD. The FLI is calculated based on triglycerides, 
gamma-glutamyl transpeptidase, BMI, and waist circumference. If 
the FLI is less than 30, NAFLD can be excluded (negative likeli-
hood ratio, 0.2), and if the FLI is more than 60, NAFLD can be di-
agnosed (positive likelihood ratio, 4.3). An FLI score of more than 
60 has a positive predictive value of 99% and a negative predic-
tive value of 15%. The AUC of the FLI was 0.84. The FLI showed 
acceptable accuracy among a Korean population.127,128
The NAFLD liver fat score (NLFS) was proposed by Kotronen et 
al.129 in a Finnish study comprising 470 subjects. That study used 
MRS to diagnose NAFLD. The NLFS is calculated based on meta-
bolic syndrome, T2DM, fasting insulin, aspartate aminotransferase 
(AST), and the AST/alanine aminotransferase (ALT) ratio. Its cutoff 
is -0.640 (sensitivity, 86%; specificity, 71%). If the NLFS is less 
than -0.640, NAFLD can be excluded, and if it is more than 
-0.640, NAFLD can be diagnosed. The AUC of the NLFS was 
0.86–0.87. NLFS showed acceptable accuracy in a Korean popu-
lation.130
The HSI was proposed by Lee et al.131 in a Korean cohort study 
of 10,724 subjects (5,462 with ultrasonography-defined NAFLD). 
The HSI is calculated based on sex, BMI, AST, ALT, and T2DM. If 
the HSI is less than 30, NAFLD can be excluded (negative likeli-
hood ratio of 0.2, sensitivity of 93.1%), and if it is more than 36, 
NAFLD can be diagnosed with high predictive accuracy (positive 
likelihood ratio of 6.1, specificity of 92.4%). The AUC of the HSI 
was 0.81. The HSI showed acceptable accuracy among a Korean 
population.132
The noninvasive surrogates just described show acceptable ac-
curacy in most cross-section studies and have been used to trace 
changes in hepatic steatosis in certain studies. However, the use-
fulness of those noninvasive surrogates in monitoring disease 
progression and evaluating treatment response should be further 
investigated.




Validated in Korean 
population
Fatty liver index (FLI)126 = (e 0.953×loge (triglycerides) + 0.139*BMI + 0.718×loge (GGT) + 0.053×waist circumference - 
15.745) / (1 + e 0.953×loge (triglycerides) + 0.139×BMI + 0.718×loge (GGT) + 0.053×waist 
circumference - 15.745) × 100
≥60, <30 Ultrasonography 
(Italy)
Yes
NAFLD liver fat score 
(NLFS)129
= -2.89 + 1.18 × metabolic syndrome (yes = 1/no = 0) + 0.45 
× diabetes (yes = 2/no = 0) + 0.15 × (fasting insulin, μU/L) 
+ 0.04 × AST + 0.94 × AST/ALT ratio
>-0.64 MRS (Finland) Yes
Hepatic steatosis index 
(HSI)131
= 8 × ALT/AST + BMI (+2, if diabetes; +2, if female) ≥36, <30 Ultrasonography 
(Korea)
Yes
BMI, body mass index; GGT, gamma-glutamyl transpeptidase; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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[Recommendations]
1.  Abdominal ultrasonography, CAP, unenhanced CT, MRS, and 
MRI-PDFF are acceptable modalities for diagnosing hepatic 
steatosis. (A1)
2.  If radiological examinations are infeasible, panels for hepatic 
steatosis can be used to assess hepatic steatosis. (B1)
Which non-invasive surrogates are available to diagnose 
NASH?
NASH is significantly associated with liver fibrosis progression 
and HCC. Non-invasive modalities to diagnose NASH are limited, 
but a prediction model based on liver stiffness, CAP (assessed us-
ing transient elastography), and ALT levels was recently proposed 
by a Korean study.133 Some studies insist that NASH can be distin-
guished from NAFL using cytokeratin-18 fragments (sensitivity, 
66%; specificity, 82%).134,135 A few studies claim that CT or MRI 
can be used to differentiate NASH from NAFLD, but no clear diag-
nostic criterion has been set.101,136 Based on the association be-
tween the viscosity shown in shear wave dispersion imaging and 
necroinflammation of the liver parenchyma, a recent study 
showed that shear wave dispersion imaging could be helpful in 
diagnosing NASH.137 The AUC of magnetic resonance elastogra-
phy (MRE) alone and that for the combined use of MRE and MRI-
PDFF in differentiating NASH from NAFL was 0.82–0.93.138,139
Recently, multiparametric MR indices, which score the results 
from various MRI techniques, have been under investigation. A 
recent Korean study found that a multiparametric MRI index using 
MRE, MRS, and T1 mapping to differentiate NASH from NAFL 
showed sensitivity of 80%, specificity of 85.2%, and an AUC of 
0.883.140 In a meta-analysis that systematically reviewed all stud-
ies using MRI to differentiate NASH from NAFL, the pooled sensi-
tivity and specificity were 87.4% and 74.3%, respectively.110 
[Recommendations]
1.  Non-invasive diagnosis of NASH remains limited, so it should 
be diagnosed by liver biopsy. (A1)
Which non-invasive surrogates are available to assess 
liver fibrosis?
The assessment of liver fibrosis is crucial in patients with NAFLD 
because the degree of liver fibrosis is significantly associated with 
long-term outcomes such as the development of HCC and liver-re-
lated death.78 Furthermore, it is important to noninvasively assess 
the regression or progression of liver fibrosis during the course of 
anti-fibrotic therapy.
Radiological surrogates
Ultrasound-based measurement techniques for liver fibrosis 
take advantage of shear wave elastography (SWE). They can be 
divided into two categories: 1) measuring the elasticity of the liver 
parenchyma using SWE without acquiring imaging data (transient 
elastography) and 2) image-based sonoelastography that acquires 
both elasticity and 2D image data (point SWE and 2D SWE). Tran-
sient elastography is widely used in clinical practice, and many re-
searchers have reported its high performance in quantifying liver 
fibrosis in NAFLD patients. In a recent meta-analysis, transient 
elastography showed high sensitivity and specificity for evaluating 
the degree of liver fibrosis in NAFLD patients.48,135,141 However, the 
accuracy of transient elastography is limited in obese patients, 
who commonly have NAFLD, making it unavailable in 5–20% of 
patients.48,142 A recent study reported that using an XL probe rath-
er than an M probe can significantly lower the failure rate of tran-
sient elastography.119,143 Image-based techniques have the advantage 
of acquiring both elasticity data and 2D images simultaneously. 
The failure rate is lower than that of transient elastography be-
cause operators can choose the area of the liver parenchyma to 
acquire elasticity data. The AUC of point SWE for quantifying liver 
fibrosis in NAFLD patients was higher than 0.8.144,145 The perfor-
mance of point SWE for advanced liver fibrosis was excellent 
(100% sensitivity and 91% specificity).146 In a recent meta-analy-
sis, the diagnostic performance of point SWE for liver fibrosis was 
similar to that of transient elastography.147 2D SWE can obtain 
elasticity data from a wider area than point SWE, and the report-
ed failure rate of 2D SWE was lower than that of point SWE.148,149 
In a prospective study, 2D SWE, MRE, and transient elastography 
had similar AUCs for advanced hepatic fibrosis (0.920, 0.929, and 
0.915, respectively).150
MRE shows high diagnostic accuracy for liver fibrosis.138,151,152 In 
contrast to transient elastography, which can examine the elastic-
ity of only a small portion of liver tissue, MRE can evaluate the 
entire liver parenchyma.152 MRE also has other advantages: opera-
tor non-dependency and no limitations for obese patients. MRE is 
the most accurate non-invasive test for liver fibrosis, with a diag-
nostic performance superior to that of transient elastogra-
phy.124,141,153 In a meta-analysis, MRE correlated well with each stage 
of liver fibrosis, with AUCs for each stage of 0.84–0.93.154,155 The 
failure rate of MRE was less than 5%, which is significantly better 
than that of transient elastography. MRE was not significantly af-
373
Seong Hee Kang, et al. 
KASL clinical practice guidelines for NAFLD
http://www.e-cmh.org https://doi.org/10.3350/cmh.2021.0178
fected by the MRI manufacturer or the strength of the magnet.156 
In addition, MRE showed robust reproducibility in repetitive ex-
aminations.157 However, the high cost of MRE limits its availability 
in clinical practice. In patients with iron deposition in the liver pa-
renchyma, it is difficult to perform MRE, and the presence of other 
infiltrative diseases, such as profound hepatic steatosis, hepatic 
congestion, or acute inflammation, can attenuate the diagnostic 
accuracy of MRE.158,159
Panels
In addition to radiological examinations, various panels of sero-
logical tests have been proposed to diagnose liver fibrosis (Table 4). 
Well-validated panels are summarized here. 
Of the noninvasive panels for liver fibrosis, the NFS has been 
studied the most. The NFS was proposed in a US study by Angulo 
et al.160 that comprised 733 subjects with biopsy-proven NAFLD. 
Two cutoffs were proposed: <-1.455 (low probability, negative 
predictive value of 88–93%) and >0.676 (high probability, posi-
tive predictive value of 82–90%).160 A meta-analysis based on 13 
studies with 3,064 subjects showed that the AUC of the NFS for 
advanced liver fibrosis was 0.85. If the NFS is less than -1.455, 
advanced liver fibrosis can be excluded with a sensitivity of 90% 
and a specificity of 60%, and if NFS is more than 0.676, advanced 
liver fibrosis can be diagnosed with a sensitivity of 67% and a 
specificity of 97%.48,160-172 Among 412 Korean subjects with biop-
sy-proven NAFLD, an NFS of less than -1.455 allowed advanced 
liver fibrosis to be excluded with a high negative predictive value 
(86.6%), and an NFS of more than 0.676 allowed advanced liver 
fibrosis to be diagnosed with a positive predictive value of 50%.173 
In another Korean study, which recruited 315 subjects with biop-
sy-proven NAFLD, the cutoff values (<-1.455 and >0.676) showed 
an AUC of 0.84 in diagnosing advanced liver fibrosis (negative 
predictive value of 89.3–95.7%).174 However, cases that fall be-
tween the cutoff values (indeterminate probability) still require a 
liver biopsy.48
The fibrosis-4 index (FIB-4) was proposed by Sterling et al. in a 
study comprising 832 subjects with human immunodeficiency vi-
rus/hepatitis C virus co-infection. FIB-4 is calculated using the 
platelet count, age, AST, and ALT. The AUC of FIB-4 for advanced 
liver fibrosis was 0.765. When the FIB-4 is less than 1.30, ad-
vanced liver fibrosis can be excluded (accuracy, 90%), and when 
FIB-4 is more than 2.67, advanced liver fibrosis can be diagnosed 
(accuracy, 80%).175 A recent study of subjects with biopsy-proven 
NAFLD showed that the diagnostic accuracy of the NFS and FIB-4 
was significantly higher than that of other noninvasive panels for 
liver fibrosis and similar to that of MRE in diagnosing advanced 
liver fibrosis.141 However, because the diagnostic accuracy of FIB-4 
was inferior to that of the NFS in a Korean study, further valida-
tion studies are required.173
The enhanced liver fibrosis (ELF) panel has recently been used 
to assess liver fibrosis in Europe. ELF was proposed by Guha et 
al.163 in a UK study comprising 192 subjects with biopsy-proven 
NAFLD. ELF is calculated based on three proteins associated with 
liver fibrosis: hyaluronic acid, tissue inhibitor of metalloproteinase 
1, and amino terminal peptide of procollagen III. The cutoff value 
and AUC of ELF for advanced liver fibrosis were 0.3576 and 0.90, 
respectively (sensitivity, 80%; specificity, 90%; positive predictive 
value, 71%; negative predictive value, 94%).163
Other serological surrogates for liver fibrosis, such as M2BPGi 
and AsAGP, have been proposed.176-179 However, because few 
data for subjects with NAFLD are available, further validation 
studies are required. The noninvasive surrogates described above 
show acceptable accuracy and prognostic values in most cross-
section studies. However, the usefulness of noninvasive surro-




Validated in Korean 
population
NAFLD fibrosis score 
(NFS)
= -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) 
+ 1.13 × impaired fasting glucose or diabetes (yes=1, 
no=0) + 0.99 × AST/ALT ratio - 0.013 × platelet count 
(×109/L) - 0.66 × serum albumin (g/dL)
<-1.455, >0.676 Liver biopsy Yes
Fibrosis-4 index  
(FIB-4)413
= Age (years) × AST [U/L]/ (platelets [109/L] × (ALT [U/L])1/2 <1.3, >2.67 Liver biopsy Yes
Enhanced liver fibrosis 
(ELF)163,414
Patented (hyaluronic acid, tissue inhibitor of 
metalloproteinase 1, amino terminal peptide of 
procollagen III as constituent variables)
0.3576 Liver biopsy Yes
NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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gates in monitoring disease progression and evaluating treatment 
response should be further investigated.
[Recommendations]
1.  Radiological examinations such as transient elastography, 
point SWE, 2D SWE, and MRE are helpful in assessing hepatic 
fibrosis. (A1) 
2.  If radiological examinations are infeasible, panels such as NFS 
or FIB-4 can be used to diagnose liver fibrosis. (B1)
Which differential tests are available for advanced 
fibrosis?
In NAFLD, liver fibrosis testing uses serologic tests, image tests, 
or liver biopsy. Because liver biopsy cannot be performed in all 
patients, an algorithm can be used to differentiate advanced fi-
brosis (Fig. 2). Advanced fibrosis can be differentiated primarily 
using transient elastography, FIB-4, and the NFS.180
When subjects are classified as intermediate risk by transient 
elastography, FIB-4, or the NFS, additional tests such as M2BPGi, 
AsAGP, ELF, SWE, or MRE can be performed. If the algorithms 
suggest advanced fibrosis, additional tests to re-evaluate the liver 
fibrosis or a liver biopsy should be considered. 
[Recommendations]
1.  Non-invasive methods such as transient elastography, FIB-4, 
and NFS are prioritized to discriminate advanced liver fibrosis. 
(A1)
2.  Serological tests, imaging tests, and liver biopsies may be 
performed as additional liver fibrosis evaluations. (B1)
Liver biopsy
What are the indications for liver biopsy?
Non-invasive tests to replace liver biopsy have been developed 
and shown high accuracy.122,181,182 However, liver biopsy remains 
the gold standard for diagnosing NAFLD.183 In practice, it is diffi-
cult to perform liver biopsy in all patients suspected of having 
NAFLD.184,185 However, liver biopsy can help with diagnosis, treat-
ment planning, and distinguishing between NAFLD and other liver 
diseases (autoimmune hepatitis, drug-induced hepatitis, Wilson’s 
disease, etc.). Liver biopsy is necessary when NASH or advanced 
liver fibrosis is suspected, as well as when other liver diseases 
cannot be excluded.186-188
Liver biopsy has several limitations. First, sampling error is a 
concern because only a small portion of the liver tissue is sampled 
during liver biopsy. Second, intra- and inter-observer variability 
occurs.189-191 Third, it carries the risk of complications such as 
bleeding and infection, as well as increased medical costs. There-





Low risk Intermediate risk High risk
Differentiation of advanced fibrosis
Additional evaluation of liver fibrosis
Consider liver biopsy
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fore, it is difficult to perform or repeat liver biopsy in all pa-
tients.192 To minimize discrepancies, it is recommended that a suf-
ficient amount of tissue be collected, a thick needle (16–18 
gauge) be used, and two or more samples of a sufficient length 
be collected.97
[Recommendations]
1.  Liver biopsy should be considered in patients suspected of 
having NASH or advanced liver fibrosis. (B1)
2.  Liver biopsy should be considered when the presence 
or severity of coexisting chronic liver disease cannot be 
excluded. (B1)
What are the histopathological features of NAFLD?
The role of liver biopsy in NAFLD diagnosis lies in differentiating 
simple steatosis (NAFL) from NASH, evaluating the extent of fi-
brosis (stage), and excluding the possibility of other liver diseases. 
NAFL is defined as the presence of ≥5% steatotic hepatocytes 
without evidence of hepatocellular injury in the form of hepato-
cyte ballooning.193 The degree of steatosis is graded as 1+ (mild, 
5–33%), 2+ (moderate, 34–66%), and 3+ (severe, ≥67%). NASH 
is diagnosed when there is evidence of hepatocellular injury (he-
patocellular ballooning) and lobular inflammation in addition to 
steatosis.193-195 Fibrosis, when present, is staged as stage 1 (peri-
venular, perisinusoidal, or periportal fibrosis), stage 2 (both zone 
3 and periportal fibrosis), stage 3 (bridging fibrosis), and stage 4 
(cirrhosis).195 
HCC surveillance and prevention
Is surveillance for HCC necessary?
Because the incidence of liver cirrhosis and HCC associated with 
NAFLD is increasing rapidly, the risk of HCC should be assessed 
and surveillance should be established in all NAFLD patients. Be-
cause the incidence of HCC in patients with NAFLD-related cirrho-
sis is more than 1.5% per year,196,197 HCC surveillance is recom-
mended if liver cirrhosis is clinically suspected.198-201
Although the incidence of HCC in patients with NAFLD was 10 
times higher than that in the normal control group,202 the inci-
dence of HCC is very low in patients with early liver fibrosis (F0–
2). However, when patients with early liver fibrosis have HCC risk 
factors (obesity, metabolic syndrome, diabetes, etc.), they become 
more likely to develop HCC. Thus, surveillance should be individu-
alized.203,204
Abdominal ultrasound is the primary surveillance test for HCC. 
However, in overweight or obese patients, it can be difficult to 
perform accurately.205,206 In those cases, CT or MRI can be used 
instead.
How can HCC be prevented?
Smoking is associated with liver fibrosis and is known to be a 
risk factor for the development of HCC. In meta-analyses and co-
hort studies, smoking increased the risk of developing HCC by 1.5 
and 1.8 times, respectively.207,208 Therefore, smoking cessation is 
recommended for NAFLD patients. The effect of alcohol consump-
tion on the development of HCC varies between studies, but in a 
meta-analysis, drinking increased the incidence of HCC by 1.2–2.1 
times. Patients with liver cirrhosis associated with NAFLD should 
abstain from alcohol because drinking it increases the risk of HCC 
and liver-related mortality.209,210
In a 32-year cohort study, diabetes increased the incidence of 
HCC by 4.6 times.211 A meta-analysis also showed that diabetes 
increased the incidence of HCC.211-215 Metformin decreased the in-
cidence of HCC, but the use of sulfonylurea and insulin increased 
the incidence of HCC by 1.6 and 2.6 times, respectively.216 Peroxi-
some proliferator activated receptor gamma (PPAR-γ) agonist and 
glucagon-like peptide-1 (GLP-1) agonist were effective in the re-
covery of NASH, but they did not show a significant association 
with the development of HCC.217-220
Dyslipidemia is associated with NASH and CVD, but the rela-
tionship with liver disease-related mortality or HCC is still lacking. 
In a meta-analysis, statin use reduced the risk of developing HCC 
by 37%.221 However, results in patients with NAFLD remain insuf-
ficient.222,223
Obesity is associated with both liver fibrosis and HCC.224 Al-
though weight loss and exercise improve both steatosis and fibro-
sis, there are insufficient studies showing that weight loss and ex-
ercise therapy reduce the incidence of HCC. Further research is 
thus needed on the association between weight loss and HCC in-
cidence.
[Recommendations]
1.  Patients with liver cirrhosis associated with NAFLD need HCC 
surveillance. (A1)
2.  To reduce the development of HCC in patients with NAFLD, 
smoking cessation, alcohol abstinence, and weight loss are 
recommended. (B1)
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TREATMENT
Who should be treated, and what is the aim of the 
treatment?
NAFLD is commonly associated with metabolic diseases such as 
obesity, diabetes, and insulin resistance. Given that NAFLD is asso-
ciated with increased mortality from CVD and liver-related compli-
cations,225,226 NAFLD patients require management and treatment 
to improve their prognosis. Treatments for NAFLD aim to reduce 
the incidence and mortality of CVD and liver-related complications, 
and they include both pharmacologic and non-pharmacologic op-
tions to improve intrahepatic inflammation and fibrosis and treat 
comorbid metabolic diseases. Lifestyle modifications such as 
weight reduction, dietary control, and exercise and treatment of 
comorbidities such as diabetes, obesity, hypertension, and dyslipid-
emia are the cornerstones of treatment for NAFLD and should be 
applied to all NAFLD patients, regardless of the degree of inflam-
mation or fibrosis. However, pharmacologic treatments should be 
applied selectively because NAFLD progresses slowly and encom-
passes a spectrum of conditions from NAFL to NASH cirrhosis.
The most important histologic marker indicating long-term 
prognosis is the severity of fibrosis,51,52,227 with stage 2 or more fi-
brosis (≥F2) being an independent predictor of liver-related com-
plications and mortality.51,52,228 The most important factor in the 
progression of fibrosis is the presence of steatohepatitis. Fibrosis 
progresses more rapidly in patients with steatohepatitis than in 
those without it,36,38 and changes in steatohepatitis are associated 
with the progression of fibrosis.229,230 Therefore, patients with he-
patic fibrosis or steatohepatitis can receive pharmacologic treat-
ment to improve their long-term prognosis.
[Recommendations]
1.  Patients with NAFLD need lifestyle modifications and treatment 
for comorbidities. (A1)
2.  Patients with NASH or hepatic fibrosis need management or 
treatment for histologic improvement. (A1)
Lifestyle modifications
What do lifestyle modifications include?
Weight reduction
Among overweight or obese (BMI >25.0 kg/m2) NAFLD pa-
tients, weight loss through lifestyle changes significantly reduced 
their liver fat content as revealed by imaging231,232 or liver biop-
sy.233-235 In patients histologically diagnosed with NAFLD, weight 
loss of more than 5–7% resulted in decreased intrahepatic fat 
content and inflammation,233,234 with greater weight loss correlat-
ing with greater histologic improvement.234 Liver fibrosis also im-
proved in 45% of patients whose weight loss was more than 
10%.234 In a meta-analysis of studies about weight loss through 
lifestyle modification, anti-obesity drugs, and surgical treatment, 
weight loss was associated with a decrease in intrahepatic fat, 
NAFLD activity score (NAS), and liver enzymes.236 Even in non-
obese NAFLD patients, intrahepatic fat content improved with a 
weight loss of 3–5%.237 Therefore, weight loss is important in 
NAFLD patients regardless of the presence of obesity.
In NAFLD patients with obesity, the rate of weight loss affects 
steatohepatitis. A study showed that weight reduction that tar-
geted a gradual decrease (maximum of 1 kg/week of body 
weight) improved both NASH and NAS.238 However, a rapid de-
crease (more than 1.6 kg/week of body weight) worsened portal 
inflammation and fibrosis in some morbidly obese patients,239 and 
rapid weight loss through bariatric surgery can lead to acute he-
patic failure.240 Therefore, progressive weight loss of less than 
1 kg/week is recommended over rapid weight loss in NAFLD pa-
tients with obesity.
Dietary therapy
Reducing the intake of total energy and controlling food in take 
are crucial aspects of NAFLD treatment. In prospective, random-
ized, controlled studies, reductions in energy intake caused 
weight loss, decreased intrahepatic fat content, decreased liver 
enzyme levels, and decreased insulin resistance.232,241,242 A daily 
intake of 1,500–1,800 kcal in men and 1,200–1,500 kcal in wom-
en can reduce total energy intake by more than 500 kcal/day.243 
However, daily caloric intake should be optimally adjusted accord-
ing to age, sex, weight, and physical activity.
Recently, the association between the ratio of macronutrients 
(carbohydrates, fats, and proteins) and the development of obesi-
ty and NAFLD has been studied. Carbohydrate intake was associ-
ated with metabolic syndrome and the severity of intrahepatic in-
flammation.244,245 In Western studies, low-carbohydrate diets were 
more effective than low-fat diets in reducing liver fat content.242 
In Korea, increased carbohydrate and fructose intake was associ-
ated with an increased prevalence of fatty liver and elevated liver 
enzymes,246 and low-carbohydrate dietary training was more ef-
fective than low-fat dietary training in reducing both liver en-
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zymes and liver fat content.247 However, both low-fat and low-
carbohydrate diets effectively reduced liver fat content.241 The 
decrease in liver fat content did not differ depending on the type 
of diet; liver fat content decreased in patients who lost more than 
7% of their body weight regardless of whether they ate a low-
carbohydrate or high-carbohydrate diet.232 In a meta-analysis 
comparing low-carbohydrate and low-fat diets, the two did not 
differ in reducing liver fat content.248 Therefore, total energy in-
take is a more important factor in NAFLD treatment than the 
composition ratio of macronutrients.
The Mediterranean diet pattern emphasizes vegetables, fruits, 
whole grains, and legumes, and the principal source of dietary 
lipids is olive oil. It also includes the moderate consumption of fish 
and shellfish, white meat, eggs, and dairy products, with red 
meat and processed meats eaten rarely and in small quantities.249 
It has a high content of monounsaturated fatty acids. The Medi-
terranean diet reduces liver fat content and makes insulin resis-
tance significantly better than low-fat diets regardless of body 
weight,250,251 and adherence to the Mediterranean diet was more 
important than adherence to a low-fat diet.251,252
Dietary control along with weight loss can help reduce hepatic 
fat content. However, studies of specific nutrients and dietary 
habits have been conducted on only small numbers of patients, 
and few have shown histologic improvement to hepatic inflamma-
tion or fibrosis. It is difficult to maintain adherence to appropriate 
dietary habits in the long run. Therefore, it is necessary to study 
an appropriate diet to which patients can maintain adherence for 
a long time that produces histological improvement. In addition, 
dietary effects can vary depending on genetic predisposition,253 
such as the presence of PNPLA3 or TM6SF2 variants, and dietary 
control needs to be individualized for each patient.
Exercise
NAFLD is associated with a low level of physical activity. In 
large-scale Korean cohort studies, prolonged sitting time and de-
creased physical activity were positively associated with the prev-
alence of NAFLD regardless of BMI,254 and moderate to vigorous 
exercise decreased the risk of developing a fatty liver or improved 
the resolution of an existing fatty liver.255 In biopsy-proven NAFLD 
patients, vigorous exercise (≥6 metabolic equivalents of task 
[METs]) was associated with a lower frequency of NASH and ad-
vanced fibrosis.256 Exercise itself decreases insulin resistance and 
reduces liver fat content regardless of body weight changes.257-262 
In a meta-analysis, exercise was found to be effective in reducing 
the liver fat content.263-265 Aerobic exercise was mainly recom-
mended at moderate or vigorous intensity (greater than 50–70% 
of maximal heart rate), and exercise for 30–60 minutes more than 
three times per week for at least 6 weeks was found to be effec-
tive.258,262,266,267 Resistance exercise was recommended at 50–70% 
of maximal strength (1-repetition maximum) for 30–60 minutes 
more than three times per week.257,266,267 According to the World 
Health Organization and United States Department of Health and 
Human Services, moderate-intensity physical activities include 
brisk walking, dancing, gardening, and carrying or moving an ob-
ject of less than 20 kg, and vigorous-intensity physical activities 
include running, fast cycling, aerobics, fast swimming, and carry-
ing or moving objects of more than 20 kg (Table 5).268,269
It is unclear which exercise is most effective. Some randomized 
controlled studies comparing aerobic exercise and resistance exer-
cise have shown that aerobic exercise more effectively reduces liv-
Table 5. Examples of moderate and vigorous physical activity
Moderate-intensity physical activity Vigorous-intensity physical activity
(3–6 METs) (>6 METs)
Brisk walking Running
Dancing Walking/climbing briskly up a hill
Slow cycling Fast cycling
Gardening Aerobics
Recreational swimming Fast swimming
Active involvement in games and sports with children Competitive sports and games (e.g., football, volleyball, basketball)
General building tasks (e.g., roofing, painting) Digging or shoveling
Carrying/moving objects of less than 20 kg Carrying/moving objects of more than 20 kg
Walking domestic animals
METs, metabolic equivalents of task.
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er fat content than resistance exercise,270 but some studies show 
similar effects from both exercise types.266,267 In recent systematic 
reviews, both aerobic and resistance exercise similarly reduced the 
liver fat content.271,272 However, resistance exercise could be more 
feasible than aerobic exercise for NAFLD patients with poor car-
diorespiratory fitness or those who cannot tolerate aerobic exer-
cise because it requires much lower energy consumption.271 Be-
cause exercise-mediated improvements in liver fat can be reversed 
to baseline levels after cessation, it is necessary to maintain exer-
cise habits.273 Therefore, the selection of exercise needs to be in-
dividualized so that it can be maintained continuously considering 
each patient’s preferences and cardiopulmonary fitness. 
[Recommendations]
1.  In overweight or obese NAFLD patients, weight loss of more 
than 5–7% results in decreased intrahepatic fat content, 
and weight loss of more than 7–10% is required to improve 
hepatic inflammation and fibrosis. (A1)
2.  To reduce intrahepatic fat content, a reduction in the total 
energy intake of more than 500 kcal/day is required. (A1)
3.  To reduce intrahepatic fat content, at least moderate-intensity 
exercise for more than 30 minutes more than 3 times per 
week is required. (B1)
What is the effect of moderate or less alcohol consump-
tion?
The effects of moderate or less alcohol consumption should be 
considered because NAFLD, by definition, includes patients whose 
alcohol consumption is insignificant. However, alcohol consump-
tion is not easy to distribute randomly, so the effects of alcohol 
consumption on NAFLD can be evaluated only through longitudi-
nal observational studies. Significant alcohol consumption (male 
≥210 g/week, female ≥140 g/week) can cause alcohol-related 
liver disease and should be avoided. However, the effects of light 
or moderate drinking vary. In some studies, light or moderate 
drinking (male <210 g/week, female <140 g/week) appears to be 
protective against fatty liver and hepatic fibrosis,274-279 but in other 
studies it was associated with the progression of NAFLD.196,280-282 
In a large cohort study in Korea, light drinking (less than 10 g/day) 
was associated with worsening in noninvasive markers of fibro-
sis,283,284 but further studies are needed.
[Recommendation]
1.  Moderate or less alcohol use in NAFLD patients requires 
attention. (B1)
What are the types, indications, effects, and side 
effects of medications for NAFLD?
Insulin sensitizers
Pioglitazone
Pioglitazone, a PPAR-γ agonist, reduces insulin resistance in the 
liver, muscle, and adipose tissue, and also reduces the amount of 
fat in the liver and hepatocellular injury by alleviating hepatic mi-
tochondrial oxidative dysfunction.285-288 In four randomized con-
trolled studies, histologic improvement of steatohepatitis was ob-
served in patients with or without diabetes who were treated 
with pioglitazone (30 or 45 mg/day) compared to placebo-treated 
patients.217,289-291 However, no improvement was observed in liver 
fibrosis, a major indicator predicting the progression of liver dis-
ease.289-293 In the Pioglitazone versus Vitamin E versus Placebo for 
the Treatment of Nondiabetic Patients with Nonalcoholic Steato-
hepatitis (PIVENS) trial, 247 nondiabetic NASH patients were ran-
domized to pioglitazone (30 mg/day), vitamin E (800 IU/day), or 
placebo and followed for 96 weeks. The primary endpoint of this 
study was a ≥2 point reduction in the NAS (one or more point 
improvement in hepatocellular ballooning and one or more point 
improvement in either the lobular inflammation or steatosis 
scores). Compared with placebo, pioglitazone showed improve-
ment in NASH (34% vs. 19%, P=0.04). This study concluded that 
the improvements observed with pioglitazone were not statisti-
cally significant because they did not reach the prespecified level 
of significance (P<0.025) for the primary outcome. However, there 
were discrepancies in the presence of hepatocellular ballooning 
between the results of pathological assessments performed local-
ly and those performed centrally from deeper cuts prepared from 
the biopsy specimens obtained, and those classification errors 
were much higher in the subjects taking pioglitazone. The resolu-
tion of steatohepatitis, the secondary outcome, was higher in the 
pioglitazone group than the placebo group (47% vs. 21%, 
P=0.001). In conclusion, pioglitazone can be considered as a 
treatment option for NASH diagnosed by liver biopsy in patients 
with or without diabetes mellitus.
However, weight gain294 is a common side effect of pioglitazone 
treatment. Other potential side effects of long-term pioglitazone 
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use in NASH patients with diabetes mellitus include lower extrem-
ity edema, muscle cramps, as well as an increased risk of frac-
tures,295 bladder cancer,296 and congestive heart failure.297
Metformin
Metformin, a commonly prescribed drug for T2DM, was expect-
ed to be beneficial in treating NASH patients, as it reduces insulin 
resistance in the liver and muscles. Moreover, metformin inhibits 
hepatic fat accumulation and glucose excretion by activating ade-
nosine monophosphate-activated protein kinase, and also de-
creases the expression of tumor necrosis factor-α.298,299 However, 
metformin has little or no effect on liver histology.300,301 Since 
metformin has a weight loss effect, it can compensate for the 
weight gain associated with pioglitazone when the two medica-
tions are used together. However, several studies, including ran-
domized controlled studies, showed that the co-administration of 
metformin and pioglitazone did not improve histological findings 
in the liver, insulin resistance in the liver, or liver enzyme levels 
compared with controls.300,302-307 Only in a retrospective study, 
long-term use (more than 6 years) of metformin in patients with 
diabetes mellitus and histologically proven NASH or advanced fi-
brosis lowered the risk of overall mortality, LT, and HCC.308 Anoth-
er retrospective study showed that diabetes mellitus increased the 
risk of death and liver-related complications such as HCC, and 
that metformin use lengthened the survival and decreased the 
risk of decompensated cirrhosis and HCC in 299 patients with 
NAFLD-associated Child-Pugh class A cirrhosis.309
GLP-1 agonist
Liraglutide, a synthetic long-acting GLP-1 receptor agonist, has 
been approved to treat diabetes mellitus and obesity. In a small 
phase 2 clinical trial of 52 patients with biopsy-proven NASH, pa-
tients receiving subcutaneous injections of liraglutide (1.8 mg/day 
for 48 weeks) achieved greater weight loss and resolution of 
NASH than those receiving placebo.218 However, its development 
as a medication for NASH has been interrupted by its frequent 
gastrointestinal side effects such as diarrhea, constipation, and 
loss of appetite.
In a phase 2 trial of semaglutide, a GLP-1 analogue, 320 pa-
tients with NASH were randomized to receive daily subcutaneous 
semaglutide (0.1 mg, 0.2 mg, or 0.4 mg) or placebo for 72 weeks. 
The proportions of patients who experienced NASH resolution 
without the exacerbation of hepatic fibrosis were 40%, 36%, and 
59%, respectively, in the treatment groups and 17% in the place-
bo group (P<0.001, semaglutide of 0.4 mg vs. placebo).310 How-
ever, the groups did not differ significantly with regard to fibrosis 
improvement. The mean percentage of weight loss was 13% for 
the 0.4 mg semaglutide group and 1% for the placebo group, 
with the semaglutide group reporting more frequent nausea, con-
stipation, and vomiting than the placebo group. Based on those 
results, semaglutide is expected to prove its benefit as a treat-
ment for NASH through additional phase 3 clinical trials.
[Recommendations]
1.  Pioglitazone is effective in improving steatohepatitis in NASH 
confirmed by liver biopsy, regardless of diabetes mellitus, 
but safety concerns about long-term treatment should be 
considered. (B1)
2.  Metformin can be used as a first-line treatment for diabetes 




Vitamin E decreases oxidative stress (which worsens NASH) and 
improves liver inflammation.311,312 In the PIVENS study, which was 
a large-scale phase 3 trial, the administration of 96-week high-
dose vitamin E (800 IU/day) produced significant improve ment in 
liver histology compared to placebo (43% vs. 19%, P=0.001),291 
but it did not improve liver fibrosis.292 The proportion of NASH 
resolution, a secondary endpoint, was 36% in the vitamin E 
group, which was higher than that in the control group (21%). 
Therefore, the use of vitamin E can be considered as biopsy-prov-
en NASH treatment in patients without diabetes mellitus.
However, the long-term use of vitamin E also carries safety con-
cerns because of the increased risk of prostate cancer or hemor-
rhagic stroke.313 Although the finding is controversial, high doses 
of vitamin E (>400 IU/day) are associated with an increased mor-
tality rate, requiring safety precautions.314-316 According to a retro-
spective study of 236 patients with biopsy‐proven NASH with 
bridging fibrosis or compensated cirrhosis, the use of 800 IU/day 
of vitamin E for more than 2 years decreased the risk of death, LT 
and decompensated cirrhosis in patients both with and without 
diabetes mellitus. However, the incidence of HCC, vascular dis-
ease, and non-hepatic cancers did not differ between the vitamin 
E users and controls.317
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[Recommendation]
1.  High-dose vitamin E (800 IU/day) can improve NASH confirmed 
by liver biopsy in non-diabetic patients, but safety should be 
considered for long-term administration. (B1)
Lipid-lowering drugs
CVD is the most common cause of death for NAFLD patients, so 
it is important to modify its risk factors.78,318-320 An increase in 
plasma lipoprotein increases the carotid intima-media thickness 
and atherosclerotic plaques, which cause CVD, and thus it is nec-
essary to prevent and treat dyslipidemia.321 Lipid lowering agents 
such as statins (hydroxy-methyl-glutaryl coenzyme A reductase 
inhibitors)322 can be considered in NAFLD patients with dyslipid-
emia.323,324 In a post-hoc analysis of the GREek Atorvastatin and 
Coronary-heart-disease Evaluation (GREACE) study, statin use de-
creased aminotransferases and poor cardiovascular outcomes in 
NAFLD patients with aminotransferases up to three times higher 
than the upper normal limit. Less than 1% of patients (seven of 
880 patients) withdrew from the study due to hepatotoxicity as-
sociated with the statin treatment; thus statin treatment seems to 
safely lower liver enzymes and reduce cardiovascular morbidity in 
patients with NAFLD.325 In a study using data from the National 
Health Information database of South Korea, statin treatment de-
creased not only the risk of NAFLD occurrence but also the devel-
opment of fibrosis attributed to NALFD, regardless of diabetes 
mellitus.326 Strict control of low density lipoprotein cholesterol 
(LDL-C) is emphasized because many NAFLD patients treated with 
statins still did not meet their LDL-C treatment targets, which can 
itself increase the incidence of CVD.327 A common adverse effect 
of statins is the asymptomatic elevation of aminotransferases, 
which usually appears within 1 year of starting statins and recov-
ers spontaneously.328 This increase in liver enzyme levels depends 
on the statin dose.329 However, because statin users and controls 
did not differ in terms of persistent and significant elevation of liv-
er enzyme levels328 or the incidence of liver and biliary tract dis-
ease,330 the administration of a statin is possible in chronic liver 
diseases, including NAFLD.331,332 However, the administration of 
statins to patients with decompensated cirrhosis or acute liver 
failure should be avoided.333-337 Statins can be used in NAFLD and 
NASH, and they are considered as a first-line treatment to lower 
LDL-C and prevent atherosclerotic CVD. If the response to the 
statin is insufficient, ezetimibe can be added.338 Omega-3 fatty 
acids are not recommended as a treatment for NASH because 
only some study results showed an effect on NASH,339 whereas 
others did not.340,341 However, they may be considered for use in 
hypertriglyceridemia with NAFLD.340,342,343
[Recommendations]
1.  Because the incidence and mortality rate of CVD in NAFLD 
are high, it is necessary to actively control the risk factors of CVD. 
(A1)
2.  In the case of dyslipidemia in NAFLD, a statin can be used to 
prevent CVD. (B1)
3.  Omega-3 fatty acids are not recommended as a treatment for 
NASH, but they can be used in NAFLD with hypertriglyceridemia. 
(B1)
New NASH drugs in development
The pathophysiology of NASH is complicated, and its interac-
tions with other metabolic diseases have not been fully elucidat-
ed. Therefore, NASH treatments are currently under development 
for a wide range of targets. The main targets are changes in in-
testinal microflora and intestinal permeability, oxidative stress, in-
sulin resistance, apoptosis, lipotoxicity, inflammation, bile acid 
metabolism, and liver fibrosis. At the time of this writing, six new 
drugs are in phase 3 clinical trials or have published intermediate 
results (Table 6). Among them, the STELLAR-3, 4 trial of an apop-
tosis signal-regulating kinase 1 inhibitor (selonsertib) in NASH 
subjects with advanced liver fibrosis344 and the RESOLVE-IT trial of 
a PPAR-α/δ agonist (elafibranor) in NASH patients with stages 
1–3 of liver fibrosis have failed to demonstrate therapeutic effica-
cy in the interim results. Consequently, the development of both 
drugs was discontinued. In the REGENERATE trial in NASH sub-
jects with hepatic fibrosis stage 1–3, the farnesoid X receptor ag-
onist (obeticholic acid; Ocaliva®) showed dose-dependent primary 
treatment efficacy, an improvement in liver fibrosis of at least 1 
stage, in the 10 mg and 25 mg treatment groups (18% and 23%) 
compared with the control group (12%) after 18 months of treat-
ment.345 However, the US Food and Drug Administration rejected 
conditional approval of the drug as a treatment for NASH, judging 
that severe itching and the increased risk of CVD caused by in-
creased LDL-C outweighed the benefits of treatment. To date, no 
drugs under development have met their efficacy targets in more 
than 50% of patients. Considering the complicated pathophysiol-
ogy of NASH and the various treatment responses observed in 
clinical trials for individual drugs, it is highly likely that combina-
tion treatments or personalized treatments will become the stan-
dard.
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Bariatric surgery and LT
What are the indications for and post-operative manage-
ment of bariatric surgery?
Bariatric surgery has been performed in NASH patients with 
obesity who did not respond to medical treatment for weight loss. 
In Western countries, bariatric surgery is considered to be indicat-
ed for patients with a BMI greater than 35 kg/m2 that is accompa-
nied by hypertension or diabetes mellitus or a BMI greater than 
40 kg/m2.284,318,346 Several studies reported significant weight loss 
in addition to improvement in NAFLD.347-351 In Korea, the Health 
Insurance Review and Assessment Service allows bariatric surgery 
to be covered by the national health insurance for patients who 
have had no response to medical treatment and lifestyle modifica-
tions and whose BMI is greater than 35 kg/m2 or 30 kg/m2 and 
associated with hypertension, diabetes mellitus, or NAFLD.
In a 5-year follow-up study of biopsy-confirmed NASH patients 
who underwent bariatric surgery, BMI, the amount of fat in the 
liver, and NAS were all found to be reduced, and histological im-
provement in the fibrosis stage was noted after surgery.352 Recent 
meta-analyses identified that bariatric surgery effectively reduced 
the amount of fat in the liver, inflammation, and fibrosis in NASH 
patients.353,354 However, histological worsening after surgery was 
observed in some patients. Therefore, well-designed, randomized 
controlled studies should be performed to confirm the benefits of 
bariatric surgery in NASH patients.348 The limitation of bariatric 
surgery is the risk of lethal liver failure that can be generated by 
rapid weight loss. Also, the safety of bariatric surgery for cirrhotic 
patients is still controversial, so a careful approach is need-
ed.355-358 Before deciding to undertake bariatric surgery, intraoper-
ative complications, long-term malnutrition, and other factors 
need to be considered comprehensively.359-361
[Recommendations]
1.  Bariatric surgery can be considered for NASH patients with 
obesity who do not respond to medical treatment and lifestyle 
modification. (B1)
2.  The effectiveness and safety of bariatric surgery have not 
been established in patients with cirrhosis. (B1)
What are the indications for LT and post-LT management? 
LT can be considered in patients with end-stage liver disease 
caused by NAFLD-associated cirrhosis, liver failure, or HCC, ac-
cording to the clinical practice guideline for LT. NASH patients ex-
perience a high risk of mortality from cardiovascular complica-
tions, so a meticulous pretransplant cardiovascular evaluation is 
needed.80,362,363 Posttransplant outcomes for NAFLD patients, in-
cluding 3- and 5-year survival, were comparable to those of non-
NAFLD patients, whereas the risk of graft failure was lower.364 
Overall survival was associated with BMI and the presence of dia-
betes mellitus. LT patients with a BMI greater than 35 kg/m2 ex-
perienced a higher transplant failure rate and lower 1-year surviv-
al rate than LT patients with a BMI lower than 35 kg/m2.365
Posttransplant management is similar to that for other NASH 
patients. Maintaining a healthy weight and diet is important, es-
pecially given that weight gain is common following LT.363,366 He-
patic steatosis367 or metabolic syndrome368 is very common after 
LT, especially in patients with a history of NASH. Thus, careful at-
tention should be paid to posttransplant management.
[Recommendations]
1.  Liver transplantation could be considered in NASH patients 
with end-stage liver disease or HCC, according to the clinical 
practice guideline for LT. (A1)
Table 6. NASH treatment drugs in phase 3 clinical trials
Drug Clinical trial Chemical type Therapeutic target
Obeticholic acid REGENERATE REVERSE Synthetic bile acid derivative Farnesoid X receptor
Selonsertib STELLAR-3, 4 (discontinued 
development)
Antifibrotic agents Apoptosis signal-regulating kinase 1
Elafibranor RESOLVE-IT (discontinued development) PPAR agonist PPAR-α/δ
Cenicriviroc AURORA Chemokine receptor antagonist CCR2, 5
Resmetirom MAESTRO-NASH Hepatic thyroid hormone receptor 
β-selective agonist
THRβ
Aramchol ARMOR Synthetic fatty acid/bile acid conjugate Stearoyl coenzyme A desaturase 1
PPAR, peroxisome proliferator-activated receptor; CCR, chemokine receptor; THR, thyroid hormone receptor.
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NAFLD IN CHILDREN AND ADOLESCENTS
Epidemiology 
What is the prevalence rate? 
The National Health and Nutrition Survey conducted between 
2015 and 2017 defined cases with ALT of 26 IU/L (boys) and 22 
IU/L (girls) as NAFLD, and the estimated prevalence of this disease 
in children was 11.2% (14.7% for boys and 7.4% for girls).369 In 
2001–2005, the prevalence was 7.8% (10.6% for boys and 4.6% 
for girls), so the prevalence is increasing, and 40–45% of obese 
adolescents have NAFLD.369,370 The obesity rate of children and 
adolescents aged 7–18 years increased from 8.4% in 2008 to 
14.3% in 2016, so the prevalence of NAFLD is expected to in-
crease rapidly in the future.371,372
Summary
1.  The prevalence of NAFLD among children and adolescents in 
Korea is increasing as their obesity rate increases.
How does NAFLD progress?
The natural course and prognosis of NAFLD in children and ado-
lescents are not well known. Unlike NAFL, NASH can progress to 
cirrhosis in children and adolescents.373 In a foreign study that fol-
lowed 66 children and adolescents with NAFLD for 20 years, the 
exacerbation of liver disease and risk of early death increased by 
14 times compared with the control group.374 There was also a 
case in which HCC occurred in a 7-year-old child diagnosed with 
NAFLD.375 In recent years, LT has increased in children, adoles-
cents, and young adults due to end-stage liver disease related to 
NAFLD.376,377
Summary
1.  NASH in children and adolescents can progress to end-stage 
liver disease, including cirrhosis, in young adults.
What genetic diseases are associated with risk factors? 
The risk factors for NAFLD in children and adolescents are obe-
sity, adolescent age, and being male.378,379 This disease is common 
in adolescence because the increased sex hormones that occur at 
puberty cause changes in insulin resistance and body composi-
tion, with the hormones of boys perhaps causing more NAFLD 
than those of girls. In patients with abdominal obesity and ob-
structive sleep apnea, NAFLD is likely to be associated with acan-
thosis nigricans.376,377
Unlike in adults, in children and adolescents, steatosis some-
times appears as a phenotype of genetic disease. Therefore, 
through medical history, examination, and testing, Wilson’s dis-
ease, Bardet-Biedl syndrome, polycystic ovary syndrome, Prader-
Willi syndrome, Turner syndrome, Cohen syndrome, alpha1-anti-
trypsin deficiency, glycogen storage disease, genetic tyrosinemia 
type 1, homocystinuria, Refsum disease, citrullinemia, and lyso-
somal acid lipase deficiency should be differentiated.373
Summary
1.  Obesity, adolescent age, and being male are risk factors for 
nonalcoholic fatty liver disease in children and adolescents. 
2.  If steatosis is found in children and adolescents, potential 
accompanying genetic diseases should be considered.
Genetic factors
Is related NAFLD related to family history and genetic 
predisposition? 
Children and adolescents with a family history of NAFLD are at 
high risk of developing it. In children and adolescents diagnosed 
with NAFLD, 59% of their siblings and 78% of their parents also 
had NAFLD. On the other hand, in obese children and adolescent 
patients without NAFLD, NAFLD was found in only 17% of their 
siblings and 37% of their parents.380 NAFLD occurs from a variety 
of causes, but family outbreaks, twin studies, and differences in 
prevalence among races confirm that more than 50% of patients 
with this disease are likely to have a genetic predisposition to it.381 
In a genome-wide association study, an increase in liver fat 
mass was associated with mutations in the PNPLA3, TM6SF2, LY-
PLAL1, and GCKR genes.382 Genetic polymorphisms reported in 
children and adolescents include MBOAT7, PNPLA3, TM6SF2, and 
GCKR.383-390 Studies also showed an association with monoallelic 
ABHD5 mutations.391
Summary
1.  Children and adolescents are at increased risk of NAFLD if 
there is a family history of it. 
2.  NAFLD in children and adolescents can be associated with 
genetic variations and genetic polymorphism.
383
Seong Hee Kang, et al. 
KASL clinical practice guidelines for NAFLD
http://www.e-cmh.org https://doi.org/10.3350/cmh.2021.0178
Screening and diagnosis
Who should be targeted for NAFLD screening, and how 
is screening conducted?
NAFLD is common in children and adolescents who are over-
weight (above the 85th percentile and below the 95th percentile 
of BMI) or obese (above the 95th percentile of BMI). Therefore, 
screening is necessary for those groups. Overweight and obesity 
are checked during school health checkups in the 4th and 6th 
grades of elementary school, the 1st grade of middle school, and 
the 1st grade of high school in Korea. In overweight young peo-
ple, screening tests are performed using liver enzyme levels.392
ALT is used as a screening method for NAFLD in overweight and 
obese children and adolescents. In 2007, the US Expert Commit-
tee also recommended AST and ALT as screening tests.393-395 
However, because the normal ranges of ALT by age and sex are 
unclear, European authorities recommended abdominal ultra-
sound along with ALT as a screening test.396 In the 2019 guide-
lines for obesity in children and adolescents, those who were 
overweight or obese and had an ALT of 26 IU/L (boys) or 22 IU/L 
(girls) or more were diagnosed with NAFLD and recommended for 
abdominal ultrasound when necessary.397 In 2017, the North 
American Society of Pediatric and Gastrointestinal Nutrition rec-
ommended ALT as a screening test for obese and overweight chil-
dren aged 9–11 years with insulin resistance, pre-diabetes, diabe-
tes, or dyslipidemia.398 Based on the limited research results 
available for the cost-effectiveness of screening tests in over-
weight and obese children and adolescents, the American Liver 
Association did not recommend screening for NAFLD using ALT in 
obese children and adolescents.399 However, the 2019 guidelines 
for pediatric and adolescent obesity did recommend screening 
tests for NAFLD and other concomitant diseases in overweight 
and obese children and adolescents.
[Recommendations]
1.  NAFLD screening tests can be performed in overweight and 
obese children and adolescents. (B1)
2.  The preferred screening test for NAFLD in children and 
adolescents is ALT, and abdominal ultrasound can also be 
performed. (B1)
What are the diagnostic methods? 
The standard test for diagnosing NAFLD is liver biopsy. Howev-
er, because that method is invasive, its application to children and 
adolescents is limited. The pathologic findings of NAFLD in chil-
dren and adolescents can differ from those found in adults. Rep-
resentative differences are that steatosis is more widely observed, 
balloon degeneration of hepatocytes and hepatic lobular inflam-
mation are milder, and inflammation and fibrosis of the portal re-
gion are often present. Sinusoid fibrosis in zone 3, which is com-
monly observed in adults, is relatively rare in NAFLD in children 
and adolescents.
As a non-invasive method for diagnosing NAFLD, a method us-
ing cytokeratin-18, which is produced during hepatocyte death, 
can be used.400 In addition, various non-invasive panels are being 
studied, but they have not yet been recommended for clinical 
practice. Other additional methods include abdominal ultrasound, 
liver fibrosis scans, and MRI-PDFF.
[Recommendations]
1.  In addition to liver biopsy, non-invasive tests such as abdominal 
ultrasound, liver fibrosis scans, and MRI-PDFF can be 
performed. (B1)
Treatment
Who should be treated, and how?
Overweight and obese children and adolescents with NAFLD 
are subject to treatment, and these patients are recommended to 
correct their lifestyle habits first. There are insufficient studies on 
the long-term prognosis of NAFLD in children and adolescents, 
and few prospective randomized controlled studies have been 
done. However, when the disease is diagnosed at an early age, 
the possibility of long-term complications is high.
Most of children and adolescents with NAFLD are associated 
with obesity, so it is important to correct lifestyle habits to im-
prove obesity. Various studies have been conducted on the cor-
rection of lifestyle habits. Based on randomized controlled stud-
ies, the North American Society of Pediatric Gastrointestinal 
Nutrition recommended in 2017 that simple sugar-added bever-
ages be restricted, moderate physical activity be increased, and 
screen time (time exposed to the screens of electronic devices 
such as TVs, computers, and smartphones) be reduced to less 
than 2 hours per day.401-403
According to the TONIC trial, a large multicenter randomized 
controlled study comparing vitamin E, metformin, and placebo in 
NAFLD patients aged 8–17 years, the three groups did not differ 
in terms of a sustained decrease in ALT. In the vitamin E group, 
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histological improvement was observed. However, long-term use 
of high-dose vitamin E is not recommended because of concerns 
about side effects.404-407 In addition, a small randomized con-
trolled study tested ursodeoxycholic acid, docosahexaenoic acid, 
and fish oil, and no significant effect was found.408,409 In conclu-
sion, no drug treatment is currently recommended for NAFLD in 
children and adolescents.
Although there is no guideline for surgical treatment of NAFLD, 
it can be performed in cases of severe obesity (BMI 97th percen-
tile or higher) based on the results of research in adults.410 In the 
domestic guidelines for obesity in children and adolescents, obe-
sity surgery is recommended when BMI is 40 or more, or 35 or 
more and accompanied by major complications related to obesity, 
and lifestyle improvements and drug treatment have produced no 
effects.397 Because children and adolescents are growing, growth 
should be considered when deciding on the timing of surgery. In 
general, surgery should be considered only when skeletal growth 
is almost complete (i.e., 13–14 years old for girls, 15–16 years old 
for boys), and it is recommended that surgery be performed when 
the Tanner stage (division stage considering the degree of devel-
opment of male and female genitals according to the stage of pu-
berty) is 4 or higher.411,412
[Recommendations]
1.  In NAFLD in children and adolescents who are overweight 
or obese, lifestyle correction such as improvement of dietary 
habits, increase in physical activity, and restriction of screen 
time is needed first. (A1)
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